+|MCK0U_'%JN4{PX}&C/_V^%2_
SYSTEM PROCESSING...
+|MCK0U_'%JN4{PX}&C/_V^%2_
SYSTEM PROCESSING...
Posted: 2025-04-24 04:41:00 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-24 04:43:31 UTC
Verified By
Rollup News
A study published in the European Heart Journal found that among statin-treated patients undergoing PCI, residual inflammation, not cholesterol risk, was associated with an increased risk of major adverse cardiovascular events (MACE) during follow-up.
Residual inflammation, not cholesterol risk, is associated with increased MACE risk in statin-treated PCI patients.
Addressing inflammatory risk may be a more appropriate strategy for reducing recurrent adverse events after PCI.
A strategy solely addressing residual cholesterol risk is unlikely to significantly reduce major adverse cardiovascular events in PCI patients.
Reducing major adverse cardiovascular events in PCI patients.
Addressing residual inflammatory risk in addition to lipid-lowering treatments.